Abstract
ObjectiveTo examine the current prevalence and cost of paediatric off-label drug prescriptions in Gansu, China, and the potential influencing factors.DesignThe prevalence of off-label prescriptions in paediatrics was evaluated according to the National Medical Products Administration drug instructions in the China Pharmaceutical Reference (China Pharmaceutical Reference, MCDEX) database. The evidence of the prescription was determined by existing clinical practice guidelines and the Thomson Grade in the Micromedex 2021 compendium. We used logistic regression to investigate the characteristics that influence paediatric off-label drug use after single-factor regression analysis.SettingA multicentre cross-sectional study of outpatient paediatric prescriptions in 196 secondary and tertiary hospitals in Gansu Province, China, in March and September 2020.ResultsWe retrieved 104 029 paediatric prescriptions, of which 39 480 (38.0%) contained off-label use. The most common diseases treated by off-label drugs were respiratory system diseases (n=15 831, 40.1%). A quarter of off-label prescriptions had adequate evidence basis (n=10 130, 25.6%). Unapproved indications were the most common type of off-label drug use (n=25 891, 65.6%). A total of 1177 different drugs were prescribed off-label, with multienzyme tablets being the most common drug (n=1790, 3.5%). The total cost of the prescribed off-label drugs was ¥106 116/day. Off-label prescriptions were less frequent in tertiary than in secondary hospitals. Topical preparations were more commonly prescribed off-label than other types of drugs. Senior-level clinicians prescribed drugs off-label more often than intermediate and junior clinicians.ConclusionOff-label drug use is widespread in paediatric practice in China. Three-quarters of the prescriptions may potentially include inappropriate medication use, resulting in a daily economic burden of about ¥81 000 in 2020 in Gansu Province with 25 million inhabitants. The management of off-label drug use in paediatrics in China needs improvement.
Funder
Chevidence Lab Child & Adolescent Health of Chongqing Medical University's Children's Hospital's Key Project in 2021
Lanzhou Science and Technology Program in 2022
Gansu Provincial Hospital Program in 2023
Reference43 articles.
1. Pediatric drug policies supporting safe and effective use of Therapeutics in children: a systematic analysis;Carmack;Health Affairs,2020
2. Off-label medication use in children, more common than we think: a systematic review of the literature;Allen;J Okla State Med Assoc,2018
3. A systematic review of off-label drug use at home and abroad for pediatrics;Li;Chinese Journal of Hospital Pharmacy,2016
4. The problems on the list and database of medicines for children and corresponding solutions;Li;Chinese Journal of Drug Evaluation,2021
5. Incentive policies for pediatric drug development;Gong;Chinese Journal of New Drugs,2022